Clinical Trials
47 trialsRAINFOL-01
Genmab
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
DELTA-101
Exelixis
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Inc
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
MK-4700-001
Merck Sharp & Dohme LLC
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PNeoVCA
Mayo Clinic
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
MK-5890-001
Merck Sharp & Dohme LLC
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Nanobiotix
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
Hummingbird Bioscience
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
Takeda
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
ABILITY-1
Medicenna Therapeutics, Inc.
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18, Inc.
STOMP
The Methodist Hospital Research Institute
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
Salubris Biotherapeutics Inc
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
DUET-4
Xencor, Inc.
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Evelo Biosciences, Inc.
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors
Silverback Therapeutics
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Silverback Therapeutics
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.